Fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group 1: Individuals receiving Pioglitazone plus Vitamin E: People in this group will receive Pioglitazone 15 mg and Vitamin E 800 mg (400 mg twice daily, Zahravi factory)
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients aged 18-65 years Patients who have been diagnosed with non-alcoholic fatty liver based on ultrasound evidence and tests People with controlled diabetes (HbA1C below 8%)
Exclusion criteria
Exclusion criteria: People with heart failure (HF) Classes 3 and 4 People with kidney failure (GFR <30) People with liver cirrhosis People with bladder cancer People with Osteoporosis Pregnant and lactating women alcohol consumption People who also use other vitamins containing vitamin E at the same time People receiving warfarin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grade ultrasound. Timepoint: At the beginning of the study, 3 months and 6 months later. Method of measurement: Sonography.;Liver Enzymes(AST , ALT). Timepoint: At the beginning of the study, 3 months and 6 months later. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile. Timepoint: At the beginning of the study, 3 and 6 months later. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Elnaz Shaseb
Tabriz University of Medical Sciences
Outcome results
None listed